



## Open Clinical Trials

May 2025

To refer a patient, please directly contact the disease specific nurse navigator.

For more information regarding trials at the University of Colorado, please visit:

<https://researchstudies.cuanschutz.edu/>

### Jump to Cancer Types

- [Breast](#)
- [Cutaneous](#)
- [Gastrointestinal](#)
- [Genitourinary](#)
- [Gynecologic](#)
- [Head and Neck](#)
- [Hematology](#)
- [Neuro-Oncology](#)
- [Phase 1, Expansion, Molecular Studies \(POEMs\)](#)
- [Radiation Oncology](#)
- [Sarcoma](#)
- [Thoracic \(Lung\)](#)

### [Common Eligibility Criteria for Clinical Trials](#)

Location Key	
AMC	Anschutz Medical Campus, Anschutz Cancer Pavilion, 1665 Aurora Ct, Aurora, CO 80045
CCMC	Cherry Creek Medical Center, 100 Cook St, Denver, CO 80206
HRH	Highlands Ranch Hospital, 1500 Park Central Dr, Highlands Ranch, CO 80129
LT	Lone Tree Medical Center, 9548 Park Meadows Dr, Lone Tree, CO 80124

### [Satellite Site Contacts](#)

Breast Cancer Medical Oncology Anschutz Medical Campus (AMC)		
Nurse Navigator	Email	Phone
Jane Jachowicz, BSN, RN	Jane.jachowicz@uchealth.org	Phone: 720-848-3537 Fax: 720-848-1774
Sara Johnson, BSN, RN	Sara.johnson@uchealth.org	
Physician Leads	Email	
Virginia Borges, MD	Virginia.borges@cuanschutz.edu	
Peter Kabos, MD	Peter.kabos@cuanschutz.edu	
Jennifer Diamond, MD	Jennifer.diamond@cuanschutz.edu	

Metastatic Breast Cancer			
Study Name	Patients	NCT#	Sites
Phase 2 trial of nab-paclitaxel, durvalumab, tremelimumab +/- vaccine	1L metastatic TNBC	<a href="#">NCT03606967</a>	AMC
Phase 2 study of tucatinib, eribulin, trastuzumab	Previously treated metastatic HER2+ breast cancer	<a href="#">NCT05458674</a>	AMC
PIKture-01 Phase 1 OKI-219 (mutant selective PI3K H1047R inhibitor)	Previously treated metastatic solid tumors with PI3K H1047R mutation	<a href="#">NCT06239467</a>	AMC
Phase 1 study of XMT-2056 (immune conjugate). <i>This trial requires hospitalization and inpatient delivery of study drug for some cycles</i>	Previously treated metastatic HER2+ breast or Gastric/GE	<a href="#">NCT05514717</a>	AMC
Phase 3 CDK4/6i + fulvestrant +/- capivasertib (AKTi)	1L metastatic HR+HER2- breast cancer	<a href="#">NCT04862663</a>	AMC, CCMC
Phase 1 study of STX-478 (mutant selective PI3K inhibitor)	Metastatic HR+HER2- breast cancer with PI3K mutation	<a href="#">NCT05768139</a>	AMC (POEMs)
Phase 2 study of elacestrant	Metastatic HR+HER2- breast cancer no prior CDK4/6i	<a href="#">NCT05596409</a>	AMC
Phase 3 study OP-1250 (SERD)	Metastatic HR+HER2-	<a href="#">NCT06016738</a>	AMC, HRH, CCMC, LT
Phase 3 study of zanidatamab + standard therapy v. trastuzumab + standard therapy	Previously treated metastatic HER2+ breast cancer	<a href="#">NCT06435429</a>	AMC, HRH, CCMC
DYNASTY-Breast02: Phase 3 DB-1303 (ADC) v. standard therapy	Metastatic HR+ HER2 low	<a href="#">NCT06018337</a>	AMC, LT, HRH, CCMC
Phase 2 study of alisertib + endocrine therapy	Metastatic HR+HER2-	<a href="#">NCT06369285</a>	AMC, HRH, CCMC
Phase 1 study of BG-C9074 (B7H4 ADC) +/- tislelizumab	Previously treated metastatic HR+HER2- or TNBC, ovarian cancer	<a href="#">NCT06233942</a>	AMC (POEMs)
Phase 1/2 study of MBRC-101 in select advanced solid tumors	Metastatic breast cancer	<a href="#">NCT06014658</a>	AMC (POEMs)
CDK4/6 Inhibitor Dosing Knowledge (CDK) Study	Metastatic breast cancer in older adults	<a href="#">NCT06377852</a>	AMC
Early-Stage Breast Cancer			
ISPY2.2 Neoadjuvant study	Stage II-III Breast cancer	<a href="#">NCT01042379</a>	AMC, LT, HRH, CCMC
TROPION-Breast04: Neoadjuvant Dato-DXd + durva v. standard therapy	Stage II-III TNBC or HR low HER2-	<a href="#">NCT06112379</a>	AMC, LT, HRH, CCMC



## Cancer Center

NCI-DESIGNATED COMPREHENSIVE  
CANCER CENTER

EMBER-4: Adjuvant imlunestrant v standard therapy	High risk HR+HER2- 2-5 years endocrine therapy	<a href="#">NCT05514054</a>	AMC, LT, HRH
DARE: Phase 2 trial of ctDNA-guided treatment	High risk HR+HER2-	<a href="#">NCT04567420</a>	AMC, LT, HRH, CCMC
OFSET: Phase 3 study of chemotherapy + ovarian suppression	Premenopausal HR+HER2- breast cancer	<a href="#">NCT05879926</a>	AMC, LT, HRH, CCMC
OptimICE-PCR: De-escalation after pCR	TNBC with pCR to neoadjuvant therapy	<a href="#">NCT05812807</a>	AMC, LT, HRN
Tailor RT: Randomized study regional RT in low-risk node+ or T3N0 breast cancer	Low-risk node+ or T3N0M0 breast cancer following surgery	<a href="#">NCT03488693</a>	AMC, CCMC, HRH, LT (RT Group)
NRG-BR007: DEBRA: Phase 3 trial of de-escalation of RT in Stage I HR+HER2- breast cancer	Stage I, HR+, HER2- breast cancer with Oncotype RS $\leq$ 18	<a href="#">NCT04852887</a>	AMC, CCMC, HRH (RT Group)
NRG-BR008: HERO: Phase 3 trial of optimized RT in low-risk HER2+ breast cancer	Early stage HER2+ breast cancer following surgery	<a href="#">NCT05705401</a>	AMC, HRH (RT Group)



<b>Cutaneous Oncology Anschutz Medical Campus (AMC)</b>		
<b>Nurse Navigator</b>	<b>Email</b>	<b>Phone</b>
Nurse navigator	melanoma@uchealth.org	Phone: 720-848-0505 Fax: 720-848-0614
<b>Physician</b>	<b>Email</b>	
Sapna Patel, MD	Sapna.p.patel@cuanschutz.edu	

<b>High-Risk Resected Melanoma</b>			
<b>Study Name</b>	<b>Patients</b>	<b>NCT#</b>	<b>Sites</b>
Phase 2 study of pembrolizumab +/- mRNA-4157 (personalized cancer vaccine)	High-risk melanoma after complete resection	<a href="#">NCT03897881</a>	AMC
<b>Advanced Melanoma</b>			
PRISM-MEL-301: Phase 3 trial of nivolumab +/- IMC-F106C (PRAME x CD3 bispecific)	1L advanced melanoma HLA-A*02:01-positive	<a href="#">NCT06112314</a>	AMC
Phase 1 study of PF-07799933 (BRAFi) in advanced tumors with BRAF alterations	Metastatic melanoma with BRAF V600E mutation post BRAF/MEKi and IO	<a href="#">NCT05355701</a>	AMC (POEMs)
Phase 1 study of DCSZ11 (anti-CD93)+/- pembro in advanced solid tumors	Previously treated metastatic melanoma	<a href="#">NCT05785754</a>	AMC (POEMs)
<b>Uveal Melanoma</b>			
DAR-UM-2: Darovasertib (PKCi) + crizotinib v. standard therapy	1L HLA-A2 negative metastatic uveal melanoma	<a href="#">NCT05987332</a>	AMC
<b>Advanced Cutaneous Malignancies in Transplant Recipients</b>			
Phase 1B/2 study of RP1 (oncolytic IO)	Solid organ or hematopoietic cell transplant recipient	<a href="#">NCT04349436</a>	AMC

Gastrointestinal Oncology Anschutz Medical Campus (AMC)		
Nurse Navigators	Email	Phone
Jamie Peterson	Jamie.Peterson@uchealth.org	Phone: 720-848-2636
Natalya Veneychuk	Natalya.Veneychuk@uchealth.org	Phone: 720-848-5456
Sarah Reynolds	Sarah.Reynolds2@uchealth.org	Phone: 720-848-0201
Marcela Mora (Spanish speaking)	Marcela.Mora@uchealth.org	Phone: 720-848-5474
Physicians	Email	
Lindsey Davis, MD	Sarah.Davis@cuanschutz.edu	
Chris Lieu, MD	Christopher.Lieu@cuanschutz.edu	
Wells Messersmith, MD	Wells.Messersmith@cuanschutz.edu	

Anal/Rectal Cancer			
Study Name	Patients	NCT#	Sites
Janus: Phase 2 trial of triplet v doubled chemo locally advanced rectal cancer	Stage II/III rectal adenocarcinoma	<a href="#">NCT05610163</a>	AMC, HRH, CCMC
Gastric, Gastroesophageal, and Gastroesophageal Junction (GEJ) Cancers			
Phase 2 study of induction SBRT and olaparib followed by pembrolizumab olaparib for gastric and GEJ cancers	2L+ with homologous recombination deficiency mutation	<a href="#">NCT05379972</a>	AMC, HRH
Phase 1 study of SGN-CEACAM5C advanced solid tumors including CRC, GC/GEJ, pancreatic cancer	2L+ advanced CRC, GC/GEJ or pancreatic cancer	<a href="#">NCT06131840</a>	AMC
Phase 2 study of induction FLOT followed by neoadjuvant chemoRT in resectable adenocarcinoma esophagus or GEJ	Newly diagnosed, resectable T3-4 or node+ adenocarcinoma esophagus or GEJ	<a href="#">NCT04028167</a>	AMC
EDDC: Phase 1 study using anti-N256-glycosylated CEACAM5/6 ADC (MMAE payload) +/- pembrolizumab	Select metastatic cancers including GI and NSCLC	<a href="#">NCT05701527</a>	AMC (POEMs)
Phase 1 study of TJ033721 in metastatic gastric, GE and esophageal adenocarcinoma	1L metastatic gastric, GE, and esophageal adenocarcinoma positive for CLDN18.2	<a href="#">NCT04900818</a>	AMC
Early-Stage Colorectal Cancer (CRC)			
CIRCULATE-US: Colon adjuvant chemotherapy based on evaluation of residual disease	Stage IIIA/B MSS colon adenocarcinoma following curative resection	<a href="#">NCT05174169</a>	AMC, LT, HRH, CCMC
Metastatic Colorectal Cancer (CRC)			
Study of RAS (ON) inhibitors in GI tumors in combination with standard therapies	1-3L metastatic RAS-mutated CRC, 1-2L metastatic RAS-mutated pancreatic cancer	<a href="#">NCT06445062</a>	AMC, LT
OrigAMI-3: Phase 3 study of FOLFIRI + amivantamab v cetuximab/bevacizumab in metastatic CRC	2L metastatic CRC KRAS/NRAS and BRAF WT	<a href="#">NCT06750094</a>	AMC
INTRINSIC: Phase 1/1b umbrella study of targeted therapies in metastatic CRC	Previously treated advanced or metastatic CRC with PIK3CA mutation +/- RAS mutation	<a href="#">NCT04929223</a>	AMC
CARAPIA-1: Phase 1 study of GCC19CART in metastatic CRC. <i>This</i>	Previously treated metastatic CRC, GCC+, MSS	<a href="#">NCT05319314</a>	AMC

<i>trial requires hospitalization and inpatient delivery of study drug for some cycles</i>			
Phase 1 study of SGN-CEACAM5C advanced solid tumors including CRC, GC/GEJ, pancreatic cancer	2L+ advanced CRC, GC/GEJ or pancreatic cancer	<a href="#">NCT06131840</a>	AMC
PUMP: Phase 3 study of systemic therapy +/- hepatic arterial infusion for unresectable CRC liver mets	Unresectable liver metastatic CRC	<a href="#">NCT05863195</a>	AMC
Phase 1 study of JNJ-89402638 for metastatic CRC	3L+ unresectable metastatic CRC	<a href="#">NCT06663319</a>	AMC
Phase 1 study of BI1831169 +/- ezabenzimab in advanced solid GI tumors	Advanced or metastatic GI tumors with no standard therapies	<a href="#">NCT05155332</a>	AMC
Phase 2 study of tiragolumab, atezolizumab, and bevacizumab in patients with refractory metastatic microsatellite stable CRC	3+ unresectable metastatic CRC (microsatellite stable)	<a href="#">NCT06784947</a>	AMC
Phase 1 study of INBRX-109 (DR5 ab) in metastatic solid tumors	Ewings sarcoma, CRC	<a href="#">NCT03715933</a>	AMC (POEMs)
Phase 1 study of PF-07934040 (KRASi) in patients	Select advanced solid tumors with KRAS mutations	<a href="#">NCT06447662</a>	AMC (POEMs)
<b>Liver Cancer</b>			
EMERALD-Y90: Phase 2 study of durvalumab + bevacizumab following transarterial radioembolization	Locoregional hepatocellular carcinoma with no extrahepatic disease	<a href="#">NCT06040099</a>	AMC
Phase 1b/2 study of TTI-101 in advanced or metastatic HCC	1-3L Unresectable, locally advanced or metastatic HCC	<a href="#">NCT05440708</a>	AMC
<b>Biliary Tract Cancer</b>			
ARTEMIDE-Biliary01: Phase 3 study of rilvegostomig + chemo as adjuvant therapy for biliary tract cancer	Adenocarcinoma of biliary tract following complete resection with curative intent	<a href="#">NCT04995523</a>	AMC, HRH
Phase 2 trial of durvalumab + gemcitabine+cisplatin as neoadjuvant therapy for high-risk resectable intrahepatic cholangiocarcinoma	Intrahepatic cholangio that is considered resectable and high-risk, untreated	<a href="#">NCT04308174</a>	AMC
Phase 1/2 study of M3814 + avelumab with hypofractionated radiation in metastatic hepatobiliary malignancies	2L+ metastatic or locally advanced cholangio or gallbladder carcinoma	<a href="#">NCT04068194</a>	AMC
<b>Pancreatic Cancer</b>			
Study of RAS (ON) inhibitors in GI tumors in combination with standard therapies	1-3L metastatic RAS-mutated CRC, 1-2L metastatic RAS-mutated pancreatic cancer	<a href="#">NCT06445062</a>	AMC, LT
Phase 1/2 study of M3814 + hypofractionated radiation for locally advanced pancreatic adenocarcinoma	Locally advanced pancreatic adenocarcinoma following 4-6 months of neoadjuvant chemo	<a href="#">NCT04172532</a>	AMC
S2001: Phase 2 study of Olaparib +/- pembrolizumab maintenance in metastatic pancreatic ca with germline BRCA1/2 mutation	Metastatic pancreatic cancer with germline BRCA1/2 mutation and prior response to platinum-based chemo	<a href="#">NCT04548752</a>	AMC, HRH
Phase 1 study of SGN-CEACAM5C advanced solid tumors including CRC, GC/GEJ, pancreatic cancer	2L+ advanced CRC, GC/GEJ or pancreatic cancer	<a href="#">NCT06131840</a>	AMC



## Cancer Center

NCI-DESIGNATED COMPREHENSIVE  
CANCER CENTER

Phase 1 study of PF-07934040 (KRASi) in patients	Select advanced solid tumors with KRAS mutations	<a href="#">NCT06447662</a>	AMC (POEMs)
EDDC: Phase 1 study using anti-N256-glycosylated CEACAM5/6 ADC (MMAE payload) +/- pembrolizumab	Select metastatic cancers including GI and NSCLC	<a href="#">NCT05701527</a>	AMC (POEMs)
Phase 1b study of ATP150/2 (vaccine), VSV-GP154 (viral vector) and ezabenlimab (ICI) in pancreatic cancer	Metastatic pancreatic ductal adenocarcinoma KRAS G12D/G12V mutation	<a href="#">NCT05846516</a>	AMC
Phase 1 study of CA-4948 (IRAK4/FLT3i) + gemcitabine+ nab-paclitaxel in metastatic pancreatic cancer	2-3L metastatic or unresectable pancreatic ductal adeno	<a href="#">NCT05685602</a>	AMC
<b>Neuroendocrine Cancers</b>			
COMPOSE: Study of peptide receptor radionuclide therapy with lutetium edotreotide v standard therapy for SSTR+ GI neuroendocrine tumors	Well-differentiated aggressive, grade 2/3, SSTR+ neuroendocrine tumors of gastroenteric or pancreatic origin	<a href="#">NCT04919226</a>	AMC
NET Retreat: Phase 2 study of <sup>177</sup> Lutetium retreatment v. everolimus in metastatic midgut neuroendocrine	Metastatic grade 1/2 midgut neuroendocrine tumors	<a href="#">NCT05773274</a>	AMC



Genitourinary Oncology Anschutz Medical Campus (AMC)		
Nurse Navigator	Email	Phone
Cyndie Harvey	Cynthia.Harvey@uchealth.org	Phone: 720-848-0170 Fax: 720-848-0180
Physician	Email	
Thomas Flaig, MD	Thomas.flaig@cuanschutz.edu	
Elizabeth Kessler, MD	Elizabeth.kessler@cuanschutz.edu	

Localized Prostate Cancer			
Study Name	Patients	NCT#	Sites
Poten-C for intermediate risk	Intermediate risk prostate cancer	<a href="#">NCT03525262</a>	AMC
EA8184: GTC (green tea) v. placebo for patients with prostate cancer	Prostate cancer in active surveillance	<a href="#">NCT04597359</a>	AMC
S2210: Neoadjuvant carboplatin for patients with localized prostate cancer and germline BRCA1/2 mutations	Localized prostate cancer with germline BRCA1/2 mutation	<a href="#">NCT05806515</a>	AMC
NRG GU010: Genomic risk stratification for unfavorable intermediate risk localized prostate cancer	Localized prostate cancer unfavorable intermediate risk	<a href="#">NCT05050084</a>	AMC (RT Group)
Pragmatic study of metformin v. lifestyle mods	Localized prostate cancer	<a href="#">NCT05515978</a>	AMC
PREDICT-RT (NRG-GU009): Phase 3 trial of de-intensification for low genomic risk and intensification for high genomic risk	High-risk prostate cancer	<a href="#">NCT04513717</a>	AMC, HRH (RT Group)
Metastatic Prostate Cancer			
S1802: SST +/- surgery or radiation	Metastatic hormone sensitive prostate cancer	<a href="#">NCT03678025</a>	AMC
NRG PROMETHEAN: Phase 2 trial of oligometastatic RT +/- androgen deprivation therapy	Oligometastatic hormone sensitive prostate cancer	<a href="#">NCT05053152</a>	AMC, HRH (RT Group)
KEYNOTE-365: Study of pembrolizumab combinations COHORT I: Carbo/Etop +/- pembro	De novo and treatment emergent neuroendocrine/small cell prostate cancer	<a href="#">NCT02861573</a>	AMC
MK-5684-003: Phase 3 study of opevesostat v. abiraterone/enzalutamide	Metastatic castration-resistant prostate cancer previously treated with hormonal agent and taxane	<a href="#">NCT06136624</a>	AMC, HRH, LT
MK-5684-004: Phase 3 study of opevesostat v. abiraterone/enzalutamide	Metastatic castration-resistant prostate cancer previously treated with hormonal agent	<a href="#">NCT06136650</a>	AMC, HRH, LT
JNJ-87189401 and JNJ-78278343	Metastatic hormone refractory docetaxel refractory prostate cancer	<a href="#">NCT06095089</a>	AMC
Bladder Cancer			
BRIDGE EA8212: BCG v. docetaxel/gemcitabine	Non-muscle invasive bladder cancer	<a href="#">NCT05538663</a>	AMC
Bond CG0070 for unresponsive to BCG Arm P	Non-muscle invasive bladder cancer unresponsive to BCG	<a href="#">NCT04452591</a>	AMC





EA8192 Preoperative durvalumab and/or chemo	Upper tract bladder cancer	<a href="#">NCT04628767</a>	AMC
MODERN: A032103 risk adapted adjuvant therapy - ctDNA testing and nivo+/- relatlimab or surveillance	Muscle invasive bladder cancer after surgery	<a href="#">NCT05987241</a>	AMC
ETCTN 10144: Olaparib for DNA repair defect tumors	2L metastatic bladder cancer	<a href="#">NCT03375307</a>	AMC
ETCTN 10483: FGFR2/3 genetic alterations erdafitinib + EV	2L metastatic bladder cancer	<a href="#">NCT04963153</a>	AMC, LT, HRH
S1937: Eribulin + gemcitabine v. standard therapy	3L+ metastatic bladder cancer post PD1i	<a href="#">NCT04579224</a>	AMC
MoonRISe-1: Phase 3 study of TAR-210 v. single agent intravesical chemotherapy for bladder cancer	Intermediate-risk non-muscle invasive bladder cancer + FGFR alterations	<a href="#">NCT06319820</a>	AMC
<b>Kidney Cancer</b>			
NEOPAX: Pembrolizumab + axitinib for RCC with IVC tumor thrombus	Neoadjuvant therapy for RCC with tumor thrombus	<a href="#">NCT05969496</a>	AMC
ETCTN 10144: Olaparib for DNA repair defect tumors	2L metastatic bladder cancer	<a href="#">NCT03375307</a>	AMC
HC-7366 + belzutifan for locally advanced or metastatic clear cell RCC	2L+ metastatic clear cell RCC	<a href="#">NCT06234605</a>	AMC
EA8211: Phase 3 study of stereotactic ablative RT for oligometastatic RCC	Oligometastatic advanced RCC	<a href="#">NCT05863351</a>	AMC, HRH (RT Group)
<b>Penile Cancer</b>			
EA8134 InPACT: Neoadjuvant chemo + ILND v chemo +RT+ILND v ILND	Penile cancer	<a href="#">NCT02305654</a>	AMC

Gynecologic Oncology Anschutz Medical Campus (AMC)			
Nurse Navigator	Email	Phone	
Clinic schedulers	-	Phone: 303-724-2066	
Physician	Email		
Brad Corr, MD	Bradley.corr@cuanschutz.edu		
Ovarian Cancer - Frontline			
Study	Patients	NCT#	Sites
GOG-3068 HOTT HIPEC: Phase 3 study of HIPEC + cisplatin v no HIPEC at time of cytoreductive surgery followed by niraparib in stage III and IV ovarian cancer	Newly diagnosed stage III/IV ovarian, primary peritoneal, and fallopian tube cancer treated with neoadj chemo	<a href="#">NCT05659381</a>	AMC
Ovarian Cancer - Maintenance			
GOG 3072 TETON: Phase 1b study of ZN-c3 (Wee1i) + chemo or bevacizumab in ovarian cancer	1-2L platinum sensitive ovarian, primary peritoneal, fallopian tube cancer no BRCA mutation	<a href="#">NCT04516447</a>	AMC
UPROAR: Phase 2 study of maintenance mirvetuximab soravtansine (ADC) and olaparib in recurrent platinum sensitive, ovarian cancer	Recurrent platinum-sensitive ovarian, peritoneal, and fallopian tube cancer	<a href="#">NCT05887609</a>	AMC
Ovarian Cancer - Recurrent			
Phase 1/2a study of AZD5335 (ADC folate receptor + TOP1i) in solid tumors	Platinum-resistant or platinum-sensitive ovarian cancer	<a href="#">NCT05797168</a>	AMC
Phase 1/2 study of VLS-1488 (KIF18Ai) in advanced high grade serous ovarian cancer	Recurrent platinum-resistant high grade serous ovarian cancer, ovarian carcinosarcoma, CN-high endometrial/uterine carcinosarcoma, uterine serous carcinoma	<a href="#">NCT05902988</a>	AMC
GOG-3087: Phase 1 study of NXP800 (HSF1i) in ovarian cancer	Platinum-resistant ovarian cancer with ARID1A mutation, up to 3 prior lines	<a href="#">NCT05226507</a>	AMC
Phase 1 study of BG-C9074 (B7H4 ADC) +/- tislelizumab	Previously treated metastatic HR+HER2- or TNBC, ovarian cancer	<a href="#">NCT06233942</a>	AMC (POEMs)
Phase I study of IMG151 (anti-FRa ADC) in ovarian cancer	Recurrent endometrial or high-grade serous epithelial ovarian cancer	<a href="#">NCT05527184</a>	AMC
Ovarian Cancer – Low Grade			
ComboMATCH: Palbociclib and binimetinib in RAS-mutant cancers	Low-grade serous ovarian cancer with RAS mutation	<a href="#">NCT05554367</a>	AMC (POEMs)
Phase 2 Trial of the Combination of the BET Inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients with Molecularly-Selected Solid Tumors (ComBET)"	HRD tumors with prior PARPi use as immediate prior therapy	NCT05327010	AMC (POEMS)

Endometrial Cancer - Presurgical			
Surgical window of opportunity study of megestrol +/- metformin for endometrial intraepithelial neoplasia	Endometrial intraepithelial neoplasia no prior therapy	<a href="#">NCT04576104</a>	AMC
Endometrial Cancer - Frontline			
NRG GY026: Phase 2/3 study of paclitaxel/carboplatin +/- Hylecta or Phesgo in HER2+ Endometrial cancer	1L Stage I-IV endometrial serous carcinoma or carcinoma HER2+	<a href="#">NCT05256225</a>	AMC, HRH, CCMC
NRG GY032: Phase 2 study of tailored adjuvant therapy in POLE-mutated p53 WT early stage endometrial cancer	1L Stage I-III endometrial cancer POLE-mutated, p53 WT, completed surgery	<a href="#">NCT06388018</a>	AMC
Endometrial Cancer - Recurrent			
NRG GY028: Phase 1b/2 study of megestrol +/- ipatasertib in metastatic endometrioid endometrial cancer	Previously treated recurrent or metastatic endometrioid endometrial cancer	<a href="#">NCT05538897</a>	AMC, HRH
GOG 3104: Phase 3 study of sacituzumab govitecan v. standard therapy in previously treated endometrial cancer	Recurrent or persistent endometrial cancer previously treated with platinum and immunotherapy (up to 4L)	<a href="#">NCT06486441</a>	AMC
Phase 1/2 study of VLS-1488 (KIF18Ai) in advanced high grade serous ovarian cancer	Recurrent platinum-resistant high grade serous ovarian cancer, ovarian carcinosarcoma, CN-high endometrial/uterine carcinosarcoma, uterine serous carcinoma	<a href="#">NCT05902988</a>	AMC
GOG-3082: Phase 1b/2 basket study of ACR-368 (CHK1/2i) +/-gemcitabine in platinum-resistant ovarian, endometrial and urothelial ca based on acrivon oncosignature	Up to 4L: Recurrent, platinum-resistant ovarian cancer, endometrial adenoca, urothelial carcinoma with Acrivol Oncosignature Status	<a href="#">NCT05548296</a>	AMC
Study of E7386 in combination with other anticancer drugs in solid tumors	Recurrent or persistent endometrial cancer previously treated with platinum and immunotherapy	<a href="#">NCT04008797</a>	AMC
Phase I study of IMG151 (anti-FRa ADC) in ovarian cancer	Recurrent endometrial or high-grade serous epithelial ovarian cancer	<a href="#">NCT05527184</a>	AMC
Uterine Leiomyosarcoma			
GOG 3088: Phase 2 study of letrozole v. observation in uterine leiomyosarcoma	Newly diagnosed ER+ uterine leiomyosarcoma	<a href="#">NCT05649956</a>	AMC, HRH
BRCA Mutation Carriers			
SOROCK: Study of salpingectomy v. salpingo-oophorectomy to reduce risk of ovarian cancer in BRCA1 carriers	BRCA1 germline mutation carriers with no prior cancer diagnosis age 35-50	<a href="#">NCT04251052</a>	AMC, HRH

Head and Neck Cancer Anschutz Medical Campus (AMC)		
Nurse Navigator	Email	Phone
Jamie Peterson	<a href="mailto:Jamie.Peterson@uchealth.org">Jamie.Peterson@uchealth.org</a>	Phone: 720-848-2636
Natalya Veneychuk	<a href="mailto:Natalya.Veneychuk@uchealth.org">Natalya.Veneychuk@uchealth.org</a>	Phone: 720-848-5456
Physician	Email	
Antonio Jimeno, MD, PhD	<a href="mailto:Antonio.jimeno@cuanschutz.edu">Antonio.jimeno@cuanschutz.edu</a>	

Head and Neck Cancer			
Study Name	Patients	NCT#	Sites
eVOLVE-HNSCC: Phase 3 study of volrustomig v. observation in unresected locally advanced HNSCC	Unresected locally advanced head and neck squamous cell carcinoma (HNSCC) who have not progressed following definitive concurrent chemoRT	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06129864">NCT06129864</a>	AMC, HRH
Phase 2 study of danvatirsen + pembrolizumab v. pembrolizumab in recurrent or metastatic HNSCC	Recurrent or metastatic HNSCC	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05814666">NCT05814666</a>	AMC, HRH
Phase 1b/2 study of amivantamab monotherapy + standard therapy in recurrent/metastatic HNSCC	Recurrent or metastatic HNSCC	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06385080">NCT06385080</a>	AMC
Phase 1 study of BL-B01D1 in metastatic NSCLC, SCLC, Esophageal SCC and HNSCC	Metastatic or unresectable NSCLC, SCLC, Esophageal SCC and HNSCC previously treated	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05983432">NCT05983432</a>	AMC (Lung)
Phase 1b study of losartan, pembrolizumab and SBRT in locoregionally recurrent refractory or oligometastatic HNSCC	locoregionally recurrent refractory or oligometastatic HNSCC	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06211335">NCT06211335</a>	AMC, HRH
Phase 2 study of docetaxel + trastuzumab v. T-DM1 for HER2+ salivary gland cancer	Recurrent, metastatic, or treatment-naïve, unresectable HER2+ salivary gland cancer	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05408845">NCT05408845</a>	AMC, HRH
Phase 2 study of darolutamide + leuprolide in metastatic AR+ salivary gland cancer	Hormone-therapy naïve recurrent and/or metastatic AR+ salivary gland cancer	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05669664">NCT05669664</a>	AMC
Phase 3 study of BRAF-targeted therapy v. cabozantinib in RAI-refractory differentiated thyroid cancers with BRAF V600E mutation	Advanced RAI-refractory differentiated thyroid cancers with BRAF V600E mutation	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06475989">NCT06475989</a>	AMC

Hematology Clinical Trials Unit Anschutz Medical Campus (AMC)		
Nurse Navigator	Email	Phone
Doc Line		Phone: 720-848-2628 (doc line)
Physician	Email	
<b>Leukemia:</b> Dan Pollyea, MD	Daniel.pollyea@cuanschutz.edu	
<b>Cell Therapy/Stem Cell Transplant:</b> Jon Gutman, MD	Jonathan.gutman@cuanschutz.edu	
<b>Lymphoma:</b> Manali Kamdar, MD	Manali.kamdar@cuanschutz.edu	
<b>Multiple Myeloma:</b> Dan Sherbenou, MD, PhD	Daniel.sherbenou@cuanschutz.edu	
<b>Benign Heme and MPNs:</b> Brandon McMahan, MD	Brandon.mcmahon@cuanschutz.edu	

Leukemia			
Study	Patients	NCT#	Sites
24-0178: Study of Mitoxantrone for venetoclax-resistant AML (PI: Kent)	Non-APL AML by WHO criteria and have been treated with first-line venetoclax/HMA (azacitidine or decitabine)	<a href="#">NCT06429449</a>	AMC
23-0273: Study of cladribine+venetoclax after failure of venetoclax+hypomethylating agent in monocytic AML (PI: McMahon)	Ages ≥ 18; Relapsed/Refractory AML; ECOG of ≤2	<a href="#">NCT06232655</a>	AMC
23-0061 KO-MEN-007: Phase 1 study of Venetoclax/Azacitidine or Venetoclax + Ziftomenib (KO-539) or Standard Induction Cytarabine/Daunorubicin (7+3) + Ziftomenib for AML (PI: McMahon)	Ages ≥ 18; documented NPM1 mutation or KMT2A rearrangement and have either newly diagnosed or relapsed/refractory AML; ECOG of ≤2	<a href="#">NCT05735184</a>	AMC
20-2350: Phase 1 study Of KPT-9274 in relapsed or refractory AML (PI: Pollyea)	Ages ≥ 18 years; non-APL AML who have not responded to or relapsed after at least one prior therapy and for whom no standard therapy that may provide clinical benefit is available; ECOG of ≤ 2	<a href="#">NCT04914845</a>	AMC
23-2063: Expanded Access Program for SNDX-5613 in Patients with Relapsed/Refractory Acute Leukemias with Genetic Alterations Associated with HOXA Overexpression (PI: McMahon)	Acute leukemia; not eligible for participation in an ongoing clinical study and have no approved treatment options.	<a href="#">NCT05918913</a>	AMC
22-1502: Dose-escalation and dose-expansion Study of UCART22	Ages ≥ 18 years; diagnosed R/R B-ALL; B-ALL blast	<a href="#">NCT04150497</a>	AMC

(Allogeneic Engineered T-cells Expressing Anti-CD22 Chimeric Antigen Receptor) in relapsed or refractory CD22+ B-cell Acute Lymphoblastic Leukemia (B-ALL) (PI: Schwartz)	expressing CD22; ECOG of 0 or 1		
<b>Myelodysplastic Syndrome Trials</b>			
22-0130: A Phase 1 study of INCB057643 in Myelofibrosis and Other Advanced Myeloid Neoplasms (PI: McMahon)	Ages ≥ 18; relapsed or refractory MF, MDS, or MDS/MPN (Part 1); ECOG of ≤2	<a href="#">NCT04279847</a>	AMC
<b>Lymphoma</b>			
22-1252 waveLine-006: Phase 2 basket study of MK-2140 as monotherapy and in combination in aggressive and indolent B-cell malignancies (waveLINE-006) (PI: Bair)	Ages ≥ 18; diagnosed aggressive or indolent B-cell malignancies; ECOG of ≤2	<a href="#">NCT05458297</a>	AMC
22-0939: Phase Ib Study of mosunetuzumab or glofitamab + CC-220 and CC-99282 in B-Cell Non-Hodgkin Lymphoma (PI: Kamdar)	Ages ≥ 18; ECOG of ≤2	<a href="#">NCT05169515</a>	AMC
19-3011: Phase 2 study of JCAR017 in adults with relapsed or refractory indolent B-cell non-Hodgkin Lymphoma (NHL) (PI: Kamdar)	Ages ≥ 18; relapsed or refractory follicular lymphoma (FL) (Grade 1, 2 or 3a) or marginal zone lymphoma (MZL) histologically confirmed < 6 mos of screening, by local pathology; FL: Received at least 1 prior line; MZL: received 2+ prior lines ; ECOG of 0 or 1	<a href="#">NCT04245839</a>	
21-2578: Phase 1/1b study of bispecific CD19 and CD22 chimeric antigen receptorCo-expressing T cells (CD19x22 CAR T) in adolescent and adult patients with relapsed and/or refractory B-NHL (PI: Kamdar)	Ages ≥ 16; Relapsed or refractory aggressive B-cell NHL; ECOG of 0 or 1	<a href="#">NCT05098613</a>	AMC
22-0054: Phase I study of CD19 Directed CAR T Cells in Adult Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Minimal Residual Disease (MRD) Positivity at First Complete Remission) (PI: Kamdar)	Ages ≥ 18; B-cell ALL in first complete morphologic remission; MRD positive; ECOG of ≤2	<a href="#">NCT05535855</a>	AMC
<b>Benign Heme</b>			
22-0305: Phase 3 study of the hepcidin mimetic rusfertide (PTG-300) in Polycythemia Vera (PI: McMahon)	Ages ≥ 18; Diagnosed polycythemia vera; ECOG of ≤2	<a href="#">NCT05210790</a>	AMC



## Cancer Center

NCI-DESIGNATED COMPREHENSIVE  
CANCER CENTER

NVL-520: Expanded access program for NVL-520 (novel ROS1 TKI)	Metastatic NSCLC with ROS1	<a href="#">NCT05118789</a>	AMC
Phase 1/2 study of amivantamab in metastatic NSCLC with ALK, ROS1 or RET gene fusions	Previously treated advanced NSCLC with ALK, ROS1, or RET gene fusions	<a href="#">NCT05845671</a>	AMC





Neuro-Oncology Anschutz Medical Campus (AMC)		
Nurse Navigator	Email	Phone
Clinic scheduler	-	Phone: 720-848-0300
Physician	Email	
Denise Damek, MD	Denise.damek@cuanschutz.edu	

Neuro-Oncology			
Study	Patients	NCT#	Sites
Phase 1 study of perioperative vorasidenib (IDH1/2i) + pembrolizumab in recurrent or progressive enhancing IDH-1 mutant astrocytomas	IDH1 mutant astrocytomas/oligodendrogliomas recurrent or progressive enhancing	<a href="#">NCT05484622</a>	AMC
GBM AGILE: Phase 2/3 platform trial evaluating multiple regimens for glioblastoma	Newly diagnosed and recurrent GBM	<a href="#">NCT03970447</a>	AMC,
Phase 1/2 trial of Selinexor (XPO1i) + temozolomide in recurrent glioblastoma	Recurrent GBM	<a href="#">NCT05432804</a>	AMC
Study of SonoCloud-9 + carboplatin v. standard of care in first recurrence GBM	1 <sup>st</sup> Recurrent GBM	<a href="#">NCT05902169</a>	AMC
Phase 1/2 study of nivolumab +/- ipilimumab + multifraction SRS in recurrent high grade radiation-relapsed meningioma	Recurrent grade II/III radiation-relapsed meningioma	<a href="#">NCT03604978</a>	AMC
A071401 Phase 2 study of SMO/AKT/NF2 inhibitors in progressive meningiomas	Progressive meningiomas with AKT1, PIK3CA or PTEN mutations	<a href="#">NCT02523014</a>	AMC
Phase 2 study of tirabrutinib (BTKi) in primary CNS lymphoma	Newly diagnosed CNS lymphoma	<a href="#">NCT04947319</a>	AMC
Phase 2 trial of erdafitinib in recurrent glioma	Recurrent or progressive IDH-WT glioma with FGFR-TACC gene fusion	<a href="#">NCT05859334</a>	AMC
Phase 2 trial of immunothera in somatically hypermutated recurrent GBM	Recurrent GBM with somatic hypermutation	<a href="#">NCT04145115</a>	AMC

Phase 1, Expansion, Molecular Studies (POEMs) Anschutz Medical Campus (AMC)		
Nurse Navigator	Email	Phone
Contact Disease Site Specific Nurse Navigator (ie Breast Cancer, GI, GU, etc.)		
Physician	Email	
Jennifer Diamond, MD	jennifer.diamond@cuanschutz.edu	
Antonio Jimeno, MD, PhD	Antonio.jimeno@cuanschutz.edu	

POEMs Studies			
Study	Patients	NCT#	Sites
Phase 1 study of INBRX-109 (DR5 ab) in metastatic solid tumors	Ewings sarcoma, CRC	<a href="#">NCT03715933</a>	AMC
Phase 1 study of CB-03-10 (AR and glucocorticoid receptor inhib) in advanced solid tumors	Advanced solid tumors	<a href="#">NCT03863145</a>	AMC
Phase 1 study of PF-07799933 (RAFi) in advanced tumors with BRAF alterations	Metastatic melanoma with BRAF V600E mutation post BRAF/MEKi and IO	<a href="#">NCT05355701</a>	AMC
Phase 1 study of mRNA-4359 + pembrolizumab in advanced solid tumors	1L NSCLC PD-L1 TPS $\geq$ 50%	<a href="#">NCT05533697</a>	AMC
ComBET: Phase 2 trial of ZEN-3694 (BETi) + talazoparib in advanced solid tumors	Advanced solid tumor prior PARPi +/-DDR (not PARP1/2) mutation	<a href="#">NCT05327010</a>	AMC
Phase 1 study of STX-478 (mutant selective PI3K inhibitor)	Metastatic HR+HER2-breast cancer with PI3K mutation	<a href="#">NCT05768139</a>	AMC
Phase 1 study of DCSZ11 (anti-CD93) as monotherapy and combo in advanced solid tumors	Melanoma and others	<a href="#">NCT05785754</a>	AMC
Phase 1 study of GS-9716 (MCL-1i) as monotherapy and in combination	Metastatic NSCLC with docetaxel	<a href="#">NCT05006794</a>	AMC
ComboMATCH: Palbociclib and binimetinib in RAS-mutant cancers	Low-grade serous ovarian cancer with RAS mutation	<a href="#">NCT05554367</a>	AMC
Phase 1 study of RMC-6291 (KRAS G12Ci) + RMC-6236 (KRASi) in KRAS G12C mutant solid tumors	Previously treated metastatic NSCLC with KRAS G12C mutation	<a href="#">NCT06128551</a>	AMC
Phase 1 study of SNS-101 (anti-VISTA) +/- cemiplimab	Select advanced solid tumors	<a href="#">NCT05864144</a>	AMC
Phase 1 study of BG-C9074 (B7H4 ADC) +/- tislelizumab	Metastatic breast and ovarian cancer	<a href="#">NCT06233942</a>	AMC
Medilink: Phase 1 study of YL211 (cMET ADC with Topo-1 payload)	Select advanced solid tumors	<a href="#">NCT06384352</a>	AMC
Phase 1/2 study of MBRC-101 in select advanced solid tumors	Metastatic breast cancer	<a href="#">NCT06014658</a>	AMC
Phase 1 study of PF-07934040 (KRASi) in patients	Select advanced solid tumors with KRAS mutations	<a href="#">NCT06447662</a>	AMC
Phase 1 study of NX-1607 (CBL-2i)	Select advanced solid tumors	<a href="#">NCT05107674</a>	AMC



Radiation Oncology Anschutz Medical Campus (AMC)		
Nurse Navigator	Email	Phone
Pam Miranda	Pamela.miranda@uchealth.org	Phone: 720-848-0224 Fax: 720-848-0113
Physician	Email	
Christine Fisher, MD	<a href="mailto:Christine.fisher@cuanschutz.edu">Christine.fisher@cuanschutz.edu</a>	

Radiation Oncology-Breast Cancer			
Study	Patients	NCT#	Sites
Tailor RT: Randomized study regional RT in low-risk node+ or T3N0 breast cancer	Low-risk node+ or T3N0M0 breast cancer following surgery	<a href="https://clinicaltrials.gov/ct2/show/study/NCT03488693">NCT03488693</a>	AMC, CCMC, HRH, LT
DEBRA: Phase 3 trial of de-escalation of RT in Stage I HR+HER2- breast cancer	Stage I, HR+, HER2- breast cancer with Oncotype RS $\leq$ 18	<a href="https://clinicaltrials.gov/ct2/show/study/NCT04852887">NCT04852887</a>	AMC, CCMC, HRH
HERO: Phase 3 trial of optimized RT in low-risk HER2+ breast cancer	Early stage HER2+ breast cancer following surgery	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05705401">NCT05705401</a>	AMC, HRH
Radiation Oncology -Lung Cancer			
MAVERICK (S1827): MRI brain surveillance +/- cranial irradiation small-cell lung	Small-Cell Lung Cancer	<a href="https://clinicaltrials.gov/ct2/show/study/NCT04155034">NCT04155034</a>	AMC, HRH
NRG-LU008: Phase 3 trial of primary lung SBRT followed by mediastinal chemo-RT locally advanced NSCLC	Locally advanced NSCLC	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05624996">NCT05624996</a>	AMC, LT, HRH
Radiation Oncology-Renal Cell Carcinoma			
EA8211: Phase 3 study of stereotactic ablative RT for oligometastatic RCC	Oligometastatic advanced RCC	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05863351">NCT05863351</a>	AMC, HRH,
Radiation Oncology-Prostate Cancer			
PREDICT-RT (NRG-GU009): Phase 3 trial of de-intensification for low genomic risk and intensification for high genomic risk	High-risk prostate cancer	<a href="https://clinicaltrials.gov/ct2/show/study/NCT04513717">NCT04513717</a>	AMC, HRH,

<b>Sarcoma Anschutz Medical Campus (AMC)</b>		
<b>Nurse Navigator</b>	<b>Email</b>	<b>Phone</b>
Erica Becker, PA-C	Erica.becker@cuanschutz.edu	Phone: 720-848-9395 Fax: 720-848-5245
Sarah Reynolds, ONN-CG, RN	Sarah.Reynolds2@uchealth.org	Phone: 720-848-0201 Fax: 720-848-0160
<b>Physician</b>	<b>Email</b>	
Breelyn Wilky, MD	Breelyn.wilky@cuanschutz.edu	
Alessandra Maleddu, MD	Alessandra.maleddu@cuanschutz.edu	

<b>Sarcoma</b>			
<b>Study</b>	<b>Patients</b>	<b>NCT#</b>	<b>Sites</b>
STRASS 2: Phase 3 study of neoadjuvant chemo followed by surgery v surgery alone high-risk retroperitoneal sarcoma	High risk retroperitoneal sarcoma (LPS/LMS)	<a href="#">NCT04031677</a>	AMC
EA7222: Phase 3 trial of doxorubicin +/- pembrolizumab undifferentiated pleomorphic sarcoma	Undifferentiated pleomorphic sarcoma and related poorly differentiated sarcomas	<a href="#">NCT06422806</a>	AMC
Open label, phase II efficacy trial of doxorubicin in combination with dual checkpoint blockade using zalifrelimab or botensilimab with balstilimab for advanced or metastatic soft tissue sarcomas	Metastatic Soft Tissue Sarcoma	<a href="#">NCT04028063</a>	AMC
A randomized blinded placebo-controlled phase 2 study of inbrx-109 in unresectable or metastatic conventional chondrosarcoma	Unresectable Metastatic Conventional Chondrosarcoma	<a href="#">NCT04950075</a>	AMC
ADI-PEG 20 or placebo plus gemcitabine and docetaxel in previously treated subjects with leiomyosarcoma	Leiomyosarcoma	<a href="#">NCT05712694</a>	AMC
Phase 3 double blind randomized placebo-controlled study of ivosidenib in pts over 18 yo with locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 systemic treatment regimen	Locally advanced or metastatic conventional chondrosarcoma with IDH1 mutation	<a href="#">NCT06127407</a>	AMC
A phase II Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients with Advanced or Metastatic Leiomyosarcoma of Soft Tissue	Metastatic Leiomyosarcoma of Soft Tissue	Not yet available	AMC
Multi-Cohort, Open-Label, Phase ½ study of DCC-3009 in Participants with Gastrointestinal Stromal Tumors	GIST	<a href="#">NCT06630234</a>	AMC



## Cancer Center

NCI-DESIGNATED COMPREHENSIVE  
CANCER CENTER

A First in-human Phase 1/2 Multicenter, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of ADCE-D01, a Humanized Anti-human uPARAP Antibody Linked to a Topoisomerase I Inhibitor, in Patients with Metastatic and/or Unresectable Soft Tissue Sarcoma	Metastatic and/or Unresectable Soft Tissue Sarcoma	<a href="#">NCT06797999</a>	AMC
Phase 1 study of INBRX-109 (DR5 ab) in metastatic solid tumors	Ewings sarcoma, SDH Deficient GIST, CRC	<a href="#">NCT03715933</a>	AMC (POEMS)

Thoracic (Lung) Oncology Anschutz Medical Campus (AMC)		
Nurse Navigator	Email	Phone
Courtney Sorensen, RN	Courtney.thoutt@uchealth.org	Phone: 720-848-2962 Fax: 720-848-0360
Physician	Email	
Tejas Patil, MD	Tejas.patil@cuanschutz.edu	
Erin Schenk, MD, PhD	Erin.schenk@cuanschutz.edu	

Early-Stage NSCLC			
Study	Patients	NCT#	Sites
NAUTIKA-1: Phase 2 study of neoadjuvant and adjuvant biomarker-selected therapy for NSCLC.	Stage IB-III NSCLC ALK fusion, ROS1 fusion, NTRK1/2/3 fusion or KRAS G12C (Neoadjuvant TKIs x 8 w), PD-L1+ > 1% (atezo + SBRT)	<a href="#">NCT04302025</a>	AMC
NRG-LU008: Phase 3 trial of primary lung SBRT followed by mediastinal chemo-RT locally advanced NSCLC	Locally advanced NSCLC	<a href="#">NCT05624996</a>	AMC, LT, HRH (RT Group)
1 <sup>st</sup> Line Metastatic NSCLC			
Phase 1 study of mRNA-4359 + pembrolizumab in advanced solid tumors	1L NSCLC PD-L1 TPS $\geq$ 50%	<a href="#">NCT05533697</a>	AMC (POEMS)
EGFR mutant NSCLC			
Phase 3 study of DZD9008 v. standard therapy for metastatic NSCLC with EGFR exon 20 insertion mutation	1L locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutation	<a href="#">NCT05668988</a>	AMC, LT
LungMAP S1900G: Phase 2 study of osimertinib + capmatinib +/- ramucirumab in	Metastatic NSCLC EGFR mutant with MET amplification as resistance	<a href="#">NCT05642572</a>	AMC
DZD9008 EAP: Expanded access program for sunvozertinib (DZD9008)	Metastatic NSCLC with EGFR Exon 20 insertion mutations	<a href="#">NCT05624996</a>	
Systimmune: Phase 1 study of BL-B01D1 (EGFR-HER3 bispecific ADC topoisomerase payload) in metastatic NSCLC	Metastatic NSCLC with EGFR mutation	<a href="#">NCT05983432</a>	AMC
Immunocore: Phase 1 study of a bispecific T-cell engager to PRAME (HLA-A*02:01) and CD3 + osimertinib. <i>Note: This trial requires hospitalization and inpatient delivery of study drug for some cycles.</i>	Metastatic NSCLC with EGFR mutation	<a href="#">NCT04262466</a>	AMC
Phase 1b/2 study of BG-60366 (EGFR CDAC protein degrader) for EGFRm NSCLC patients	Metastatic NSCLC with EGFR mutation	<a href="#">NCT06685718</a>	AMC
ALK, ROS1, or RET rearranged NSCLC			
NVL-655 EAP: Expanded access program for NVL-665 (novel ALK TKI)	Metastatic NSCLC with ALK	<a href="#">NCT05384626</a>	AMC
NVL-520: Expanded access program for NVL-520 (novel ROS1 TKI)	Metastatic NSCLC with ROS1	<a href="#">NCT05118789</a>	AMC

Phase 1/2 study of amivantamab in metastatic NSCLC with ALK, ROS1 or RET gene fusions	Previously treated advanced NSCLC with ALK, ROS1, or RET gene fusions	<a href="#">NCT05845671</a>	AMC
<b>MET or HER2 altered NSCLC</b>			
Enliven: Phase 1 study of ELVN-002 (HER2 TKI) +/- T-DxD for metastatic HER2 mutant NSCLC	Previously treated NSCLC with HER2 mutation	<a href="#">NCT05650879</a>	AMC
SWOG S1900K: Phase 2 study of tepotinib +/- ramucirumab for MET exon 14 skip NSCLC	MET exon skip metastatic NSCLC	<a href="#">NCT06031688</a>	AMC
SystImmune: Phase 1 study of BL-B01D1 (EGFR-HER3 bispecific ADC topoi payload) metastatic NSCLC	HER2 Exon 20 mutated metastatic NSCLC	<a href="#">NCT05983432</a>	AMC
<b>KRAS or BRAF altered NSCLC</b>			
Genentech: Phase 1 study of a Pan-KRAS Inhibitor RO7673396	Metastatic NSCLC with KRAS mutation	<a href="#">NCT05240898</a>	AMC
Rev Med: Phase 1 study of RMC-6291 (KRAS G12Ci) + RMC-6236 (KRASi) in KRAS G12C mutant solid tumors	Previously treated metastatic NSCLC with KRAS G12C mutation	<a href="#">NCT06128551</a>	AMC (POEMs)
Phase 1 study of PF-07934040 (KRASi) in patients	Select advanced solid tumors with KRAS mutations	<a href="#">NCT06447662</a>	AMC (POEMs)
<b>2<sup>nd</sup> Line and Beyond Metastatic NSCLC: ADCs, cytotoxics, radiation</b>			
Medilink: Phase 1 study of YL211 (cMET ADC with Topo-1 payload)	Select advanced solid tumors	<a href="#">NCT06384352</a>	AMC (POEMs)
Phase 1 study of GS-9716 (MCL-1i) as monotherapy and in combination	Metastatic NSCLC with docetaxel	<a href="#">NCT05006794</a>	AMC (POEMs)
Phase 1 study of MBRC-101 (anti-EPHA5 antibody and MMAE payload) in Advanced Refractory Solid Tumors	Select metastatic cancers including breast and NSCLC	<a href="#">NCT06014658</a>	AMC (POEMs)
EDDC: Phase 1 study (all-comers) using anti-N256-glycosylated CEACAM5/6 ADC (MMAE payload) +/- pembrolizumab	Select metastatic cancers including GI and NSCLC	<a href="#">NCT05701527</a>	AMC (POEMs)
<b>2<sup>nd</sup> Line and Beyond Metastatic NSCLC: Immunotherapy agents and Small Molecules</b>			
Immunocore: Phase 1/2 study of IMC-F106C as single agent and in combination with IO in HLA-A*02:01-positive patients with PRAME-positive cancers	HLA-A*02:01-positive patients with PRAME-positive cancers including NSCLC adeno or squamous	<a href="#">NCT04262466</a>	AMC
Zymeworks: Phase 1 study of ZW171, mesothelin-CD3 bispecific T cell engager, in solid tumors. <i>This trial requires hospitalization and inpatient delivery of study drug for some cycles.</i>	Previously treated select solid tumors	<a href="#">NCT06523803</a>	AMC
<b>Small Cell Lung Cancer</b>			
MAVERICK (S1827): MRI brain surveillance +/- cranial irradiation small-cell lung	Small-Cell Lung Cancer	<a href="#">NCT04155034</a>	AMC, HRH
NRG-CC009: Randomized study of SRS vs hippocampal-avoidant WBRT for ≤ 10 brain mets	Metastatic SCLC with brain mets	<a href="#">NCT04804644</a>	
Harpoon: Phase 1 / 2 study of HPN328-4001, Trispecific T-cell activating construct to CD3, HAS, and	Metastatic SCLC	<a href="#">NCT04471727</a>	AMC





DLL3. <i>This trial requires hospitalization and inpatient delivery of study drug for some cycles</i>			
SystImmune: Phase 1 study of BL-B01D1 (EGFR-HER3 bispecific ADC topoi payload) metastatic NSCLC	HER2 Exon 20 mutated metastatic NSCLC and SCLC	<a href="#">NCT05983432</a>	AMC
<b>Mesothelioma and Thymic Malignancies</b>			
AZ Evolve: Phase 3 study of volrustomig (PD1/CTLA4 bispecific) + chemotherapy vs investigators choice for unresectable, untreated mesothelioma		<a href="#">NCT04302025</a>	AMC
Zymeworks: Phase 1 study of ZW171, mesothelin-CD3 bispecific T cell engager, in solid tumors. <i>This trial requires hospitalization and inpatient delivery of study drug for some cycles.</i>	Previously treated select solid tumors	<a href="#">NCT06523803</a>	AMC

Satellite Site Contacts		
	Physician Leads	Nurse Navigators
CCMC	Scott Kono, MD ( <a href="mailto:Scott.Kono@CUAnschutz.edu">Scott.Kono@CUAnschutz.edu</a> )	Lanie Wolff ( <a href="mailto:lanie.wolff@uchealth.org">lanie.wolff@uchealth.org</a> )
HRH	Elaine Lam, MD ( <a href="mailto:Elaine.Lam@CUAnschutz.edu">Elaine.Lam@CUAnschutz.edu</a> )	Tera Stewart ( <a href="mailto:Tera.Stewart@CUAnschutz.edu">Tera.Stewart@CUAnschutz.edu</a> ) and Kara Ickler ( <a href="mailto:Kara.Ickler@CUAnschutz.edu">Kara.Ickler@CUAnschutz.edu</a> )
LT	Corbin Eule, MD ( <a href="mailto:Corbin.Eule@CUAnschutz.edu">Corbin.Eule@CUAnschutz.edu</a> )	Crystal Stribling ( <a href="mailto:CrystalD.Stribling@uchealth.org">CrystalD.Stribling@uchealth.org</a> )

Common Eligibility Criteria for Clinical Trials	
<b>Performance Status</b>	ECOG 0-1 Karnofsky Performance Status $\geq$ 60
<b>Age</b>	Age $\geq$ 18 years (ask for sarcoma trials)
<b>Measurable disease</b>	<p><b>Lesions that can be accurately measured in at least one dimension</b> with a minimum size requirement:</p> <ul style="list-style-type: none"> <li>• <b>For CT or MRI scans:</b> <ul style="list-style-type: none"> <li>○ The lesion must be <math>\geq 10</math> mm in its longest diameter.</li> <li>○ For lymph nodes, the short axis must be <math>\geq 15</math> mm to be considered measurable.</li> </ul> </li> <li>• <b>For physical exam or clinical measurement:</b> <ul style="list-style-type: none"> <li>○ The lesion must be <math>\geq 10</math> mm in its longest dimension and should be measurable with a caliper or ruler.</li> </ul> </li> <li>• <b>For ultrasound:</b> <ul style="list-style-type: none"> <li>○ Lesions can only be considered measurable if they are confirmed by CT or MRI measurements.</li> </ul> </li> </ul> <p><b>Non-Measurable Lesions:</b></p> <ul style="list-style-type: none"> <li>• Lesions that do not meet the criteria above are classified as <b>non-measurable</b>.</li> <li>• Please note that bone lesions (unless there is soft tissue extension), pleural effusions, or ascites are <b>not</b> considered measurable disease.</li> </ul>
<b>Adequate organ and bone marrow function</b>	<p><b>Bone marrow:</b> ANC <math>\geq</math> 1.5, Hgb <math>\geq</math> 9.0 (without recent transfusion), platelets <math>\geq</math> 100 (without recent transfusion).</p> <p><b>Hepatic:</b> AST and ALT <math>&lt;</math> 2 x ULN, bilirubin <math>&lt;</math> 2.0.</p> <p><b>Renal:</b> CrCl <math>\geq</math> 50 mL/min.</p> <p><b>Cardiovascular:</b> No symptomatic congestive heart failure; no MI, CVA, or unstable angina in the past 6 months.</p> <p><b>Pulmonary:</b> History of ILD requiring steroids (protocol dependent).</p> <p><b>Neurologic:</b> If brain metastases are present, they must have been treated and not progressing.</p>